Perspective Therapeutics (CATX) Enterprise Value Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Perspective Therapeutics | 380.23 Mn | 380.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.72% |
| Dec 31, 2025 | -72.11% |
| Sep 30, 2025 | -145.82% |
| Jun 30, 2025 | -171.72% |
| Mar 31, 2025 | -175.11% |
| Dec 31, 2024 | -134.79% |
| Sep 30, 2024 | -132.26% |
| Jun 30, 2024 | -122.87% |
| Mar 31, 2024 | -95.09% |
| Dec 31, 2023 | -3.26% |
| Sep 30, 2023 | -14.36% |
| Jun 30, 2023 | -52.58% |
| Mar 31, 2023 | -51.85% |
| Dec 31, 2022 | -50.45% |
| Sep 30, 2022 | -49.46% |
| Jun 30, 2022 | -44.18% |
| Mar 31, 2022 | -41.44% |
| Dec 31, 2021 | -38.26% |
| Sep 30, 2021 | -35.10% |
| Jun 30, 2021 | -38.81% |
| Mar 31, 2021 | -41.07% |
| Dec 31, 2020 | 5.32% |
| Sep 30, 2020 | -4.09% |
| Jun 30, 2020 | 30.35% |
| Mar 31, 2020 | -17.42% |
| Dec 31, 2019 | -18.92% |
| Jun 30, 2019 | 21.34% |
| Mar 31, 2019 | 23.06% |
| Dec 31, 2018 | -12.25% |
| Sep 30, 2018 | -11.71% |
| Jun 30, 2018 | -3.38% |
| Mar 31, 2018 | -4.15% |
| Dec 31, 2017 | -5.03% |
| Sep 30, 2017 | -7.61% |
| Jun 30, 2017 | -27.40% |
| Mar 31, 2017 | -32.75% |
| Dec 31, 2016 | -28.30% |
| Sep 30, 2016 | -53.77% |
| Jun 30, 2016 | -42.44% |
| Mar 31, 2016 | -27.27% |
| Dec 31, 2015 | -35.38% |
| Sep 30, 2015 | -9.16% |